Outlook Therapeutics, Inc. Banner Image

Outlook Therapeutics, Inc.

  • Ticker OTLK
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Outlook Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in Cranbury, New Jersey
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulationMore of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway.
4.8 / 5.0 (112)

Outlook Therapeutics, Inc. reports have an aggregate usefulness score of 4.8 based on 112 reviews.

Outlook Therapeutics, Inc.

Most Recent Annual Report

Outlook Therapeutics, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Outlook Therapeutics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!